50 related articles for article (PubMed ID: 28611261)
1. Non-neoplastic Portal Vein Thrombosis in HCV Cirrhosis Patients: Is it an Immuno-Inflammatory Disorder?
Abu El-Makarem MA; El-Akad AF; Elian MM; Sherif TM; El-Shaheed RA; Abd El Fatah AS; Sayed DM; Bakry RM; Mahmoud AM
Ann Hepatol; 2017; 16(4):574-583. PubMed ID: 28611261
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Prediction of portal vein thrombosis in chronic cirrhosis patients using data-driven precision medicine model.
Li Y; Gao J; Zheng X; Nie G; Qin J; Wang H; He T; Wheelock Å; Li CX; Cheng L; Li X
Brief Bioinform; 2023 Nov; 25(1):. PubMed ID: 38221905
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil extracellular traps formation may be involved in the association of propranolol with the development of portal vein thrombosis.
Xu X; Xu S; Zhang Y; Wang L; Yan C; Xu Z; Zhao Q; Qi X
Thromb Res; 2024 Jun; 238():208-221. PubMed ID: 38733693
[TBL] [Abstract][Full Text] [Related]
4. Associations of antiphospholipid antibodies with splanchnic vein thrombosis: a systematic review with meta-analysis.
Qi X; De Stefano V; Su C; Bai M; Guo X; Fan D
Medicine (Baltimore); 2015 Jan; 94(4):e496. PubMed ID: 25634200
[TBL] [Abstract][Full Text] [Related]
5. Platelet Activation Is Upregulated in Cirrhotic Patients with Portal Vein Thrombosis.
Zhao F; Ding J; Cui J; Zhu M; Zhao W
Thromb Haemost; 2024 May; ():. PubMed ID: 37827507
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of warfarin in cirrhotic patients with non-symptomatic portal vein thrombosis: a multicenter, randomized controlled trial.
Lu S; Chen J; Zhang R; Luo T; Ma L; Xu P; Ding H; Zeng X; Wu B; Shi Y; Liu C; Mu Y; Chen S; Wang J
Expert Rev Gastroenterol Hepatol; 2024; 18(1-3):5-12. PubMed ID: 38236640
[TBL] [Abstract][Full Text] [Related]
7. Predictive model for non-malignant portal vein thrombosis associated with cirrhosis based on inflammatory biomarkers.
Nie GL; Yan J; Li Y; Zhang HL; Xie DN; Zhu XW; Li X
World J Gastrointest Oncol; 2024 Apr; 16(4):1213-1226. PubMed ID: 38660630
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 4D Flow MRI-Derived Relative Residence Time as a Marker for Cirrhosis Associated Portal Vein Thrombosis.
Hyodo R; Takehara Y; Ishizu Y; Nishida K; Mizuno T; Ichikawa K; Horiguchi R; Kurata N; Ogura Y; Yokoyama S; Naganawa S; Jin N; Ichiba Y
J Magn Reson Imaging; 2024 Mar; ():. PubMed ID: 38490816
[TBL] [Abstract][Full Text] [Related]
9. Expression of PVT-1 and miR-29a/29b as reliable biomarkers for liver cirrhosis and their correlation with the inflammatory biomarkers profile.
Khalaf SE; Abdelfattah SN; Khaliefa AK; Daoud SA; Yahia E; Hasona NA
Hum Exp Toxicol; 2024; 43():9603271241251451. PubMed ID: 38685136
[TBL] [Abstract][Full Text] [Related]
10. Etiology and Complications of Portal Vein Thrombosis.
Trebicka J; Strassburg CP
Viszeralmedizin; 2014 Dec; 30(6):375-80. PubMed ID: 26288604
[TBL] [Abstract][Full Text] [Related]
11. Intestinal obstruction induced by portal vein thrombosis in a female undergoing oral contraceptive therapy: a case report with comprehensive review.
William M; Yogi TN; Bhusal A; Habib M; Raza AA; Ahmad W; Yadav AK; Rawal OK; Pathik P
Ann Med Surg (Lond); 2024 May; 86(5):3146-3153. PubMed ID: 38694303
[TBL] [Abstract][Full Text] [Related]
12. Should all dialysis patients with hepatitis C be treated? If so, before or after kidney transplantation?
Jadoul M; Martin P
Semin Dial; 2017 Sep; 30(5):395-397. PubMed ID: 28786139
[TBL] [Abstract][Full Text] [Related]
13. Portal vein thrombosis after hepatitis C eradication with direct acting antiviral therapy.
Stine JG; Prakash S; Northup PG
Liver Int; 2018 Jan; 38(1):185-186. PubMed ID: 28782876
[No Abstract] [Full Text] [Related]
14. Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.
Lee JW; Kim W; Kwon EK; Kim Y; Shin HM; Kim DH; Min CK; Choi JY; Lee WW; Choi MS; Kim BG; Cho NH
PLoS One; 2017; 12(6):e0179094. PubMed ID: 28614389
[TBL] [Abstract][Full Text] [Related]
15. Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population.
Kim BH; Lim YS; Kim EY; Kong HJ; Won YJ; Han S; Park S; Hwang JS
J Gastroenterol Hepatol; 2018 Feb; 33(2):475-483. PubMed ID: 28612951
[TBL] [Abstract][Full Text] [Related]
16. Risk Behaviors for HIV and HCV Infection Among People Who Inject Drugs in Hai Phong, Viet Nam, 2014.
Duong HT; Jarlais DD; Khuat OHT; Arasteh K; Feelemyer J; Khue PM; Giang HT; Laureillard D; Hai VV; Vallo R; Michel L; Moles JP; Nagot N;
AIDS Behav; 2018 Jul; 22(7):2161-2171. PubMed ID: 28612212
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C.
Afsari A; Lee E; Shokrani B; Boortalary T; Sherif ZA; Nouraie M; Laiyemo AO; Alkhalloufi K; Brim H; Ashktorab H
Dig Dis Sci; 2017 Aug; 62(8):2159-2165. PubMed ID: 28612194
[TBL] [Abstract][Full Text] [Related]
18. Racial Disparities in Hepatitis C Treatment Eligibility.
Sims OT; Pollio DE; Hong BA; North CS
Ann Hepatol; 2017; 16(4):530-537. PubMed ID: 28611273
[TBL] [Abstract][Full Text] [Related]
19. Expression of Natural Killer Cell Inhibitory Receptors is Associated with Significant Liver Injury in Chronic Hepatitis C in Children.
Mania A; Kaczmarek M; Kemnitz P; Figlerowicz M; Sikora J; Sluzewski W; Zeromski J
Ann Hepatol; 2017; 16(4):521-529. PubMed ID: 28611271
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
